Escitalopram

Escitalopram has been studied in 27 papers since 2016: 8 trials and 6 observational studies in people, 2 in animals, 10 reviews; 13 in the past year. It is an approved medicine. The newest paper, Oct 30, 2026: “Comparative efficacy and safety of nonhormonal prescription drugs for vasomotor symptoms in women with breast cancer: a systematic review and network meta-analysis”.

InterventionApproved 2002

27 papers study it6 more mention it16 findingsUpdated

PubChemChEBIMeSH

2 new papers in 30 daysSee all 33 papers on escitalopram

At a glance

The findings reach people, from one lab or study. 8 independent labs in 5 countries; 192 trials, none about aging, 79 with no results posted.

“Escitalopram significantly reduced both anxiety and vasomotor symptom severity in perimenopausal women”
Both Perimenopausal Vasomotor Symptoms and associated anxiety disorder be managed with Escitalopram : An experience at a tertiary care HospitalJournal of University Medical & Dental College2026doi:10.37723/jumdc.v17i1.978

None of its findings points the other way.

Cells, worms or flies, mice and humans: a single group.
  • 8 independent labs in 5 countries
  • 192 trials, none about aging, 79 with no results posted
  • Funders: Fudan University and others
  • 26 of 192 trials sponsored by its developers
  • Human trial8
  • Humans6
  • Animals1
  • Model organisms1

Studies in people

2 studies gave escitalopram to people and measured what changed.

What changedDesignPeopleSource

down: Decreases anxiety

down: Decreases vasomotor symptoms

Trial12 weeks346 peopleWomen30–75 yearsPostmenopausal women; Midlife adults; Older adults; perimenopausal women with vasomotor symptoms and anxietyJournal of University Medical & Dental College, Apr 11, 2026

down: Decreases hot flashes

down: Decreases Menopause Rating Scale

Randomized trialten weeks26 peopleWomenIn patients with breast cancerJournal of psychosomatic obstetrics and gynaecology, Oct 14, 2021

What did studies of escitalopram find?

14

Studies of escitalopram measured 14 outcomes, among them vasomotor symptoms, vasomotor symptoms and anxiety.

Vasomotor symptoms

downin humans1

1 study
  1. Escitalopram decreases vasomotor symptoms in humans (breast cancer-related vasomotor symptoms; compared with placebo) (SMD -1.08, 95% CI -1.80 to -0.37).

    “Five interventions were significantly more effective than placebo: escitalopram (SMD -1.08, 95% CI -1.80 to -0.37)”

    Reviewbreast cancer-related vasomotor symptoms; compared with placebofemales

    Comparative efficacy and safety of nonhormonal prescription drugs for vasomotor symptoms in women with breast cancer: a systematic review and network meta-analysis

    Frontiers in pharmacology

More on Vasomotor symptoms

Vasomotor symptoms

downin humans1

1 study
  1. Escitalopram decreases vasomotor symptoms in humans (perimenopausal women with vasomotor symptoms and anxiety).

    “Escitalopram significantly reduced both anxiety and vasomotor symptom severity in perimenopausal women”

    Human trialperimenopausal women with vasomotor symptoms and anxiety10 mg daily12 weeksfemalesn = 346

    Both Perimenopausal Vasomotor Symptoms and associated anxiety disorder be managed with Escitalopram : An experience at a tertiary care Hospital

    Journal of University Medical & Dental College

Anxiety

downin humans1

1 study
  1. Escitalopram decreases anxiety in humans (perimenopausal women with vasomotor symptoms and anxiety).

    “Escitalopram significantly reduced both anxiety and vasomotor symptom severity in perimenopausal women”

    Human trialperimenopausal women with vasomotor symptoms and anxiety10 mg daily12 weeksfemalesn = 346

    Both Perimenopausal Vasomotor Symptoms and associated anxiety disorder be managed with Escitalopram : An experience at a tertiary care Hospital

    Journal of University Medical & Dental College

More on Anxiety

Depressive symptoms

downin humans1

1 study
  1. Escitalopram decreases depressive symptoms in patients with major depressive disorder.

    “Escitalopram and venlafaxine effectively manage depressive symptoms and vasomotor instability in patients with major depressive disorder.”

    Reviewin patients with major depressive disorderfemales

    FIGO best practice recommendations for the mental health of women at menopausal age

    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics

More on Depressive symptoms

Cellular senescence

upin human cells1

1 study
  1. Escitalopram induces cellular senescence in human cells.

    “in human BJ fibroblasts, escitalopram triggered premature cellular senescence”

    CellsBJ fibroblasts

    Escitalopram accelerated aging via impaired IIS/autophagy signaling pathway

    GeroScience

More on Cellular senescence

Autophagy

downin worms1

1 study
  1. Escitalopram inhibits autophagy in worms.

    “leading to the subsequent suppression of autophagy.”

    Model organisms

    Escitalopram accelerated aging via impaired IIS/autophagy signaling pathway

    GeroScience

More on Autophagy

Healthspan

downin worms1

1 study
  1. Escitalopram impairs healthspan in worms.

    “escitalopram administration at juvenile, young, or old adult stages significantly shortens lifespan and impairs healthspan in Caenorhabditis elegans.”

    Model organisms

    Escitalopram accelerated aging via impaired IIS/autophagy signaling pathway

    GeroScience

Lifespan

downin worms1

1 study
  1. Escitalopram shortens lifespan in worms.

    “escitalopram administration at juvenile, young, or old adult stages significantly shortens lifespan”

    Model organisms

    Escitalopram accelerated aging via impaired IIS/autophagy signaling pathway

    GeroScience

Depression

downin humans1

1 study
  1. Escitalopram decreases depression in humans (post-hip fracture rehabilitation in skilled nursing facility).

    “Instead of doxepin, a highly anticholinergic antidepressant, the resident is effectively transitioned to escitalopram, resulting in a stable mood.”

    Human trialpost-hip fracture rehabilitation in skilled nursing facilityfemales

    The Pharmacist's Role in Age-Friendly Mobility

    The Senior care pharmacist

More on Depression

Menopause Rating Scale

downin humans1

1 study
  1. Escitalopram decreases Menopause Rating Scale in patients with breast cancer.

    “They could both decrease the total score of MRS.”

    Human trialin patients with breast cancer10 mgten weeksfemalesn = 26

    Escitalopram and progressive muscle relaxation training are both effective for the treatment of hot flashes in patients with breast cancer: a randomized controlled trial

    Journal of psychosomatic obstetrics and gynaecology

More on Menopause Rating Scale

Hot flashes

downin humans1

1 study
  1. Escitalopram decreases hot flashes in patients with breast cancer.

    “PMRT and escitalopram could effectively decrease number and duration of diurnal and nocturnal HFs in patients with breast cancer”

    Human trialin patients with breast cancer10 mgten weeksfemalesn = 26

    Escitalopram and progressive muscle relaxation training are both effective for the treatment of hot flashes in patients with breast cancer: a randomized controlled trial

    Journal of psychosomatic obstetrics and gynaecology

More on Hot flashes

Geriatric depression

downin humans1

1 study
  1. Escitalopram decreases geriatric depression in humans.

    “Both groups improved significantly on depression severity (HAM-D score), but not on cognitive outcomes at six months.”

    Human trial6 months

    Memantine can protect against inflammation-based cognitive decline in geriatric depression

    Brain, behavior, & immunity - health

More on Geriatric depression

All 14

What is escitalopram linked with?

2

Studies link escitalopram with 2 measures: mortality and hemorrhagic stroke.

Mortality

upin humans1RR 1.09

1 study
  1. Escitalopram is associated with mortality in humans (new prescription compared with sertraline or paroxetine) (2.86% vs. 2.63%; RR 1.09, 95% CI 1.01 to 1.18).

    “but was associated with a higher risk of mortality (2.86% vs. 2.63%, RR 1.09, 95% CI 1.01 to 1.18).”

    Humansnew prescription compared with sertraline or paroxetine90 days

    Risk of Ventricular Arrhythmia with Citalopram and Escitalopram: A Population-Based Study

    PloS one

Hemorrhagic stroke

upin humans1RR 1.33

1 study
  1. Escitalopram is linked with a higher risk of hemorrhagic stroke in humans following traumatic brain injury (RR 1.33, 95% CI 1.02–1.74).

    “escitalopram (RR, 1.33; 95% CI, 1.02-1.74) and sertraline (RR, 1.46; 95% CI, 1.10-1.94) were associated with an increase in the risk of hemorrhagic stroke.”

    Humansfollowing traumatic brain injury

    Risk of Stroke Among Older Medicare Antidepressant Users With Traumatic Brain Injury

    The Journal of head trauma rehabilitation

More on Hemorrhagic stroke

Has escitalopram been tested in people?

0 of 192 about aging

Yes: 8 trials and 6 observational studies in people have been published, and 192 trials are registered.

Approved

Repurposing

40 of 82

In trials

  • Psychological Well-Being

    Phase 4Terminated2 trials

  • Behavior

    Phase 2Results posted1 trial

  • Self-injurious behavior

    Phase 2Terminated1 trial

Stopped

  • NCT00660062TerminatedMajor depressive disorder

    Slow inclusion

  • NCT01244724TerminatedMajor depressive disorder

    Unable to recruit targeted #

  • NCT01787240TerminatedMajor depressive disorder

    Recruitment difficulties

  • NCT03993457TerminatedMajor depressive disorder

    terminated during COVID due to inability to see participants in person.

  • NCT04697693TerminatedMajor depressive disorder

    Unable to recruit participants in a timely fashion due to COVID pandemic

  • NCT00464191TerminatedBipolar disorder

    The study has been terminated because too few patients have been recruited

All 11

Trial sponsors

Funding

1 grant since 2019

São Paulo Research Foundation

Latest

Dec 2025: 3Jan 2026: 1Feb 2026: 0Mar 2026: 3Apr 2026: 2May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 1Oct 2026: 3Nov 2026: 013 papers in 12 months

See all 33 papers on escitalopram